Blog
Looking For A Specific Post? Search Below.
The Science Behind Medical Weight Loss Programs
Losing weight involves far more than just diet and exercise; it's a complex science with many factors at play. Medical weight loss programs, like those…
Address
Email Us
Phone
Fax
The information on this website is for informational purposes only; it is deemed accurate but not guaranteed. It does not constitute professional advice. Testimonials are not a guarantee, warranty or prediction of what your experience with us will be. By providing contact information, users acknowledge and give explicit consent to be contacted via the methods of communication provided, including SMS. Message and data rates may apply. Message frequency may vary. Reply STOP to opt out.
Compounded GLP-1 medications are patient-specific medication prescribed by a licensed healthcare provider based on a medical assessment and compounded in a 503(a) Compounding Pharmacy or 503(b) Outsourcing Facility. The Shot Spot exclusively works with licensed compounding pharmacies in the United States.
Compounded medications do not undergo pre-market review or an FDA-approval process. They may differ in efficacy, safety, risk, and side-effect profiles from commercially available or FDA-approved drugs. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications.
The Shot spot does not offer the following FDA-approved medications: Rybelsus®, Ozempic®, Wegovy®, Zepbound® or Mounjaro®. If you wish to recieve one of these medications, speak to your local healthcare provider.
Ozempic® (semaglutide), Wegovy® (semaglutide), and Generic Liraglutide are not compounded. Ozempic® and Generic Liraglutide are FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider's discretion. Wegovy® is FDA-approved for weight loss. Ozempic® and Wegovy® are the registered trademarks of Novo Nordisk A/S. The Shot Spot is not affiliated with or endorsed by Novo Nordisk A/S.
Novo Nordisk Inc. is the only company in the United States with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®. Novo Nordisk Inc. does not sell semaglutide to any entities for use in compounding.
Eli Lilly and Company is the only company in the United States with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®. Eli Lilly and Company does not sell tirzepatide to any entities for use in compounding.
NUVEW | Copyright 2026 All Rights Reserved | Accessibility Notice | Privacy Policy